ライフサイエンスコーパス: respiratory disease

1 e systemic and often fatal neurologic and/or respiratory disease.

2 up to 30% of immunocompromised patients with respiratory disease.

3 Influenza A viruses cause widespread human respiratory disease.

4 arly strong associations for lung cancer and respiratory disease.

5 iabetes, cardiovascular disease, and chronic respiratory disease.

6 d help to prevent the development of chronic respiratory disease.

7 articles (UFPs) on the etiology of childhood respiratory disease.

8 in the last 5 years are associated with mild respiratory disease.

9 and at distances greater than 7 km for fatal respiratory disease.

10 drugs, a disorder termed aspirin-exacerbated respiratory disease.

11 wine populations and plays multiple roles in respiratory disease.

12 deaths, of which 55 were due to nonmalignant respiratory disease.

13 eatment of ILC2-mediated allergic asthma and respiratory disease.

14 reased susceptibility to viral-induced upper respiratory disease.

15 al exposure is an important, global cause of respiratory disease.

16 ive treatment option for aspirin-exacerbated respiratory disease.

17 of allergic disease, in particular allergic respiratory disease.

18 ble to all patients with aspirin-exacerbated respiratory disease.

19 tagonists for concomitant cardiovascular and respiratory disease.

20 surfactant that works in an animal model of respiratory disease.

21 the risk of asthma in offspring and allergic respiratory disease.

22 mize the risk of vaccine-associated enhanced respiratory disease.

23 sitization to aspirin in aspirin-exacerbated respiratory disease.

24 al virus (RSV) is a major cause of pediatric respiratory disease.

25 to the study of fundamental lung biology and respiratory disease.

26 human health as the leading cause of severe respiratory disease.

27 rgic rhinitis and asthma among other chronic respiratory diseases.

28 rapeutic target for treating pain, itch, and respiratory diseases.

29 as proved effective in patients with chronic respiratory diseases.

30 cular diseases (CVDs), stroke, diabetes, and respiratory diseases.

31 a population level, but not to other chronic respiratory diseases.

32 the outcome of experimental rodent models of respiratory diseases.

33 bolism to the pathobiology of several common respiratory diseases.

34 assessment to measure key events leading to respiratory diseases.

35 dity and mortality in many neuromuscular and respiratory diseases.

36 exacerbations, and comorbidities of chronic respiratory diseases.

37 tem of humans, leading to moderate-to-severe respiratory diseases.

38 can serve as a model for understanding human respiratory diseases.

39 in particular, can provide insights into oro-respiratory diseases.

40 r the development and progression of chronic respiratory diseases.

41 ent treatment for these chronic inflammatory respiratory diseases.

42 ional factors across a range of nonmalignant respiratory diseases.

43 ns of genetic overlap between COPD and other respiratory diseases.

44 dized mortality rates by county from chronic respiratory diseases.

45 ) was developed for the inhaled treatment of respiratory diseases.

46 ortality rates from 1980 to 2014 for chronic respiratory diseases.

47 eled that might play a role in chronicity of respiratory diseases.

48 on of defined 3D hAT2 cultures as models for respiratory diseases.

49 on-years; HR, 1.29 [95% CI, 1.22-1.36]), and respiratory disease (0.6 vs 0.5 per 1000 person-years; H

50 , 0.36), stroke (0.21%; 95% PI: 0.08, 0.35), respiratory diseases (0.26%; 95% PI: 0.07, 0.46), and ch

51 43, 1.44-4.10; p=0.002), parental history of respiratory disease (1.44, 1.02-2.04; p=0.040), and low

52 sease, 625 with diabetes, 1,004 with chronic respiratory disease, 1,538 with cancer, and 1,065 with n

53 ardiovascular disease (9867), cancer (7687), respiratory disease (2161), diabetes mellitus (119), inj

54 vous diseases; (3) circulatory diseases; (4) respiratory diseases; (5) digestive diseases; (6) muscul

55 es were infectious diseases (7.8%-15.1%) and respiratory diseases (6.0%-7.6%; P<0.001 for both), wher

56 Aspirin-exacerbated respiratory disease (AERD) is a mechanistically distinct

57 Aspirin-exacerbated respiratory disease (AERD) is characterized by 3 clinica

58 Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, c

59 Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, r

60 Aspirin-exacerbated respiratory disease (AERD) is characterized by the clini

61 Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eo

62 evere nasal polyposis in aspirin-exacerbated respiratory disease (AERD) is unknown.

63 eases, including asthma, aspirin-exacerbated respiratory disease (AERD), inflammatory bowel disease,

64 pendent in vivo model of aspirin-exacerbated respiratory disease (AERD).

65 -respiratory symptoms in aspirin-exacerbated respiratory disease (AERD).

66 is a cardinal feature of aspirin-exacerbated respiratory disease (AERD).

67 sal polyps (CRSwNP), and aspirin-exacerbated respiratory disease (AERD).

68 espiratory syndrome virus (PRRSV) is a major respiratory disease agent in pigs that causes enormous e

69 evalence and determinants of noncommunicable respiratory disease among adults living in Chikhwawa Dis

70 the leading cause of hospital admission for respiratory disease among infants aged <1 year.

71 matter (PM) in air is associated with infant respiratory disease and childhood asthma, but limited ep

72 ecognised as a leading cause of severe acute respiratory disease and deaths among infants and vulnera

73 ing virus associated with outbreaks of acute respiratory disease and encephalitis.

74 ment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk), was used to

75 nd has application in the broader context of respiratory disease and for drug screening.

76 rus (RSV) infections remain a major cause of respiratory disease and hospitalizations among infants.

77 onavirus HKU1 (HCoV-HKU1) is associated with respiratory disease and is prevalent worldwide, but an i

78 er less than or equal to 2.5 mum (PM2.5)) on respiratory disease and lung cancer mortality is poorly

79 of aspirin is unique to aspirin-exacerbated respiratory disease and not observed in subjects with as

80 pollution has been associated with childhood respiratory disease and other adverse outcomes.

81 nts and young children, causing considerable respiratory disease and repeat infections that may lead

82 ) is an important viral pathogen that causes respiratory disease and suppresses immune responses in c

83 to constrain the mechanisms of WSOM-induced respiratory diseases and contribute to PM(2.5) regulatio

84 Noncommunicable respiratory diseases and exposure to air pollution are t

85 d illness can also be associated with severe respiratory diseases and high mortality rates.

86 The relationship between respiratory diseases and individual cardiovascular disea

87 osome data, three health outcomes related to respiratory diseases and its integration with the transc

88 nfectious and are the leading cause of human respiratory diseases and may trigger severe epidemics an

89 Chronic conditions, including cardiac and respiratory diseases and mental health conditions, were

90 Given the high prevalence of chronic respiratory diseases and the high cost associated with b

91 ory response/disease, organismal injury, and respiratory diseases and were involved in regulation of

92 ular diseases, cancer, diabetes, and chronic respiratory diseases) and only for people aged 30-70 yea

93 4 (95% CI: 1.00, 1.30) for fatal or nonfatal respiratory disease, and 1.12 (95% CI: 1.06, 1.19) for m

94 n, tuberculosis infection, diabetes, chronic respiratory disease, and blindness health programmes; pr

95 th, including cancer, heart disease, stroke, respiratory disease, and infection.

96 nic and ischemic heart disease, nonmalignant respiratory disease, and lung, skin, bladder, and kidney

97 ular disease, heart disease, stroke, cancer, respiratory disease, and other causes, with risk reducti

98 mmon respiratory virus that can cause severe respiratory disease, and postinfluenza invasive pulmonar

99 the efficacy of common therapies for chronic respiratory disease, and the potential of manipulation o

100 ce and rats, including hepatitis, enteritis, respiratory diseases, and encephalomyelitis in the centr

101 cardiovascular diseases, cancers, injuries, respiratory diseases, and hospital admissions, and we ca

102 ity (related to heart disease, chronic lower respiratory diseases, and neoplasms) recorded in 2006 fo

103 e to external causes; 3,152 (9%) were due to respiratory diseases; and 3,115 (9%) were due to infecti

104 h (cancer, diabetes, cardiovascular disease, respiratory disease, anxiety, and depression) associated

105 Chronic respiratory diseases are an important cause of death and

106 Importantly, both chronic respiratory diseases are frequent comorbidities, ensurin

107 cular diseases on mortality in patients with respiratory disease, are unclear.

108 ce that they have a lower risk of dying from respiratory disease as a whole.

109 fication of basic mechanisms of allergic and respiratory diseases as well as the translation of these

110 MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human

111 sociated CV-A16 and CV-A6, as well as severe respiratory disease-associated EV-D68, have developed a

112 e increased risk for hospital admissions for respiratory disease, asthma, and pneumonia peaked at lag

113 an 65 years or with an underlying cardiac or respiratory disease) at 30 ICUs in France; follow-up was

114 ary bacterial species associated with bovine respiratory disease (BRD) and is responsible for signifi

115 Bovine Respiratory Disease (BRD) is the leading cause of mortal

116 Bovine respiratory disease (BRD) is the most common infectious

117 romycin use in calves at high risk of bovine respiratory disease (BRD) on antimicrobial resistance ge

118 derstanding of the pathophysiology of bovine respiratory disease (BRD).

119 efits many patients with aspirin-exacerbated respiratory disease but provides no benefit for aspirin-

120 levels in subjects with aspirin-exacerbated respiratory disease, but not in those with aspirin-toler

121 Here we engineered breath biomarkers for respiratory disease by local delivery of protease-sensin

122 olyps of 3 patients with aspirin-exacerbated respiratory disease by using fluorescence-activated cell

123 h relevant tracheobronchial proxies of human respiratory diseases can be developed.

124 ent stroke, heart disease, diabetes, chronic respiratory disease, cancer, and neurodegenerative disea

125 bacco smoking is highly addictive and causes respiratory disease, cardiovascular disease and multiple

126 der to implement such therapies into chronic respiratory disease care pathways.

127 rom the lowest socioeconomic group and fatal respiratory disease cases aged >/=60 y were underreprese

128 ease cases and 18% (95% CI 16%-21%) of fatal respiratory disease cases residing at 10 km distance fro

129 Coronavirus Disease 19 (COVID-19) is a respiratory disease caused by severe acute respiratory s

130 Diphtheria is a potentially fatal respiratory disease caused by toxigenic Corynebacterium

131 fluenza virus infection in humans.IMPORTANCE Respiratory diseases caused by influenza viruses still p

132 to protect U.S. soldiers against the severe respiratory diseases caused by these viruses.

133 However, severe acute respiratory disease, caused by severe acute respiratory

134 virus disease 2019 (COVID-19), an infectious respiratory disease causing thousands of deaths and over

135 ginally arose as part of a major outbreak of respiratory disease centered on Hubei province, China.

136 nic, recurrent and incurable allergy-related respiratory disease characterized by inflammation, bronc

137 There are a number of respiratory diseases characterized by the presence of ex

138 Chronic lower respiratory diseases (CLRDs), including chronic obstruct

139 tients with AERD on average have more severe respiratory disease compared with patients with chronic

140 hesis similar to that in aspirin-exacerbated respiratory disease, completely blocked the physiologic

141 Bovine respiratory disease complex (BRDC) is one of the most im

142 for airway microbiome assessment in chronic respiratory disease.Conclusions: Metagenomic analysis of

143 Initially conceptualized as a respiratory disease, COVID-19 is increasingly recognized

144 icum, the primary etiologic agent of chronic respiratory disease (CRD) in poultry, leads to prolonged

145 pplications (apps) for patients with chronic respiratory diseases (CRDs).

146 may eventually lead to tissue remodeling and respiratory disease.Cystic fibrosis is caused by mutatio

147 mmation in subjects with aspirin-exacerbated respiratory disease, despite reducing nasal symptoms.

148 d death from cardiovascular, infectious, and respiratory diseases, diabetes, and all non-cardiovascul

149 Analysis by qPCR of 271 porcine respiratory disease diagnostic submission samples identi

150 erinatal and nutritional conditions, chronic respiratory diseases, diarrhoea, and fever of unknown or

151 heart disease, perinatal conditions, chronic respiratory diseases, diarrhoea, respiratory infections,

152 While pigs generally developed severe respiratory disease due to effective virus replication a

153 to maternal smoking had higher rates of late respiratory disease during childhood.

154 isk for bronchopulmonary dysplasia (BPD) and respiratory disease during early childhood after preterm

155 nd some evidence of positive associations of respiratory disease ED visits with biomass burning PM2.5

156 sociations between source-specific PM2.5 and respiratory disease ED visits.

157 sociations between source-specific PM2.5 and respiratory disease emergency department (ED) visits and

158 pecial significance in the context of recent respiratory disease epidemics.

159 al antibodies (MAbs) 72/8 and 69/1, enhanced respiratory disease (ERD) in mice following H3N2 virus c

160 SV has been associated with serious enhanced respiratory disease (ERD).

161 ne has been associated with serious enhanced respiratory disease (ERD).

162 highly contagious pathogens that cause fatal respiratory disease every year, with high economic impac

163 Only in subjects with aspirin-exacerbated respiratory disease, exhaled nitric oxide (P < 0.05), pl

164 tions for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely u

165 apy, the aetiological treatment for allergic respiratory diseases, has demonstrated to be an effectiv

166 ardiovascular diseases, cancers, and chronic respiratory diseases have been the main drivers of the g

167 disease (HR = 1.08, 95% CI: 1.00, 1.16), and respiratory disease (HR = 1.20, 95% CI: 1.14, 1.26).

168 heart disease (HR, 1.06; 95% CI, 1.02-1.09), respiratory disease (HR, 1.04; 95% CI, 1.00-1.09), and c

169 itively associated with the risk of incident respiratory diseases, hypertension and myocardial infarc

170 tudy was to examine the impact of smoking on respiratory diseases, hypertension and myocardial infarc

171 und between smoking and the risk of incident respiratory diseases, hypertension and myocardial infarc

172 sIgE]) when studying time trends in allergic respiratory disease in adults within the current millenn

173 quency of SERPINA1 variation associated with respiratory disease in at-risk smokers.

174 to cause fatal outbreaks of encephalitis and respiratory disease in Bangladesh and India on a near-an

175 lisepticum, the etiological agent of chronic respiratory disease in chickens, exhibits enhanced patho

176 e matter and emergency department visits for respiratory disease in four U.S. cities.

177 a A virus is the major cause of influenza, a respiratory disease in humans and animals.

178 frequent outbreaks of severe neurologic and respiratory disease in humans with high case fatality ra

179 myxovirus that causes fatal encephalitis and respiratory disease in humans.

180 er end-point events involving RSV-associated respiratory disease in infants warrants further study.

181 utcomes of include abortion, fetal death and respiratory disease in newborn piglets.

182 Here we show that SARS-CoV-2 causes a respiratory disease in rhesus macaques that lasts betwee

183 n and control strategies for noncommunicable respiratory disease in sub-Saharan Africa are needed.

184 mortality, cardiovascular disease (CVD), and respiratory disease in the prospective urban and rural e

185 Asthma is a chronic respiratory disease in which airway inflammation is a ke

186 ella bronchiseptica is an etiologic agent of respiratory diseases in animals and humans.

187 ence of sex or obesity in the development of respiratory diseases in humans and animals, the mechanis

188 mal diseases, including both mild and severe respiratory diseases in humans.

189 nd human metapneumovirus (HMPV) cause severe respiratory diseases in infants and elderly adults(1).

190 len in infancy is a risk factor for allergic respiratory diseases in later childhood, but effects on

191 Occupational respiratory diseases in workers of peach tree crops have

192 tion to the burden of the major nonmalignant respiratory diseases, including airway diseases; interst

193 stantially to the burden of multiple chronic respiratory diseases, including asthma (PAF, 16%); chron

194 are critical processes in the development of respiratory diseases, including asthma.

195 gic and clinical feature of muco-obstructive respiratory diseases, including chronic obstructive pulm

196 unction is critical in the pathology of many respiratory diseases, including cystic fibrosis.

197 critical role in the pathogenesis of several respiratory diseases, including cystic fibrosis.

198 Nationally, the mortality rate from chronic respiratory diseases increased from 40.8 (95% uncertaint

199 Aspirin-exacerbated respiratory disease is a severe form of chronic rhinosin

200 pulmonary eosinophilia linked with allergic respiratory disease is able to promote antiviral host de

201 ong-term antibiotic use for managing chronic respiratory disease is increasing; however, the role of

202 of new safe and effective therapies for such respiratory diseases is an arduous and expensive process

203 have been associated with cardiovascular and respiratory diseases, it is not known whether exposure t

204 ently identified coronavirus that causes the respiratory disease known as coronavirus disease 2019 (C

205 Millions of people are affected by respiratory diseases, leading to a significant health bu

206 ramyxoviruses include global causes of lower respiratory disease like the parainfluenza viruses, as w

207 associated with multiple diseases including, respiratory diseases like asthma and chronic obstructive

208 striction by challenging aspirin-exacerbated respiratory disease-like (ptges1(-/-)) mice with aspirin

209 ymphoid cells (ILC2s) in aspirin-exacerbated respiratory disease-like Ptges(-/-) mice.

210 ficantly related to increased mortality from respiratory disease, lung cancer, and cardiovascular dis

211 Pertussis is a severe respiratory disease mainly caused by Bordetella pertussi

212 The presence of respiratory disease may affect tissue oxygenation and en

213 , heart diseases (men: 1.2; women: 0.3), and respiratory diseases (men: 0.3; women: 0.2), and a decre

214 in terms of excess life-years lost were for respiratory diseases (men: 0.9; women: 1.4) and alcohol

215 f type 2 inflammation in aspirin-exacerbated respiratory disease.Methods: Forty-two subjects with asp

216 FEV(1) had an increased risk of nonmalignant respiratory disease mortality (using inverse probability

217 onger LTL associates with protection against respiratory disease mortality [HR = 0.854(0.804-0.906),

218 Significantly elevated respiratory disease mortality risk associated with long-

219 l anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) asthma is characterized by c

220 steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is a chronic inflammatory co

221 l anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD).

222 been studied in depth for NSAID-exacerbated respiratory disease (NERD) and NSAID-exacerbated cutaneo

223 NSAID-exacerbated respiratory disease (NERD) is recognized as a distinct a

224 l anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD).

225 he predominant clinical presentation is with respiratory disease, neurological manifestations are bei

226 RATIONALE: Despite the high burden of respiratory disease, no spirometry reference values for

227 ill into the first group: NSAIDs-exacerbated respiratory disease, NSAIDs-exacerbated cutaneous diseas

228 working fluid (MWF) has been associated with respiratory disease.Objectives: As part of a public heal

229 flammation characterizes aspirin-exacerbated respiratory disease.Objectives: To determine whether hig

230 Canine influenza is a respiratory disease of dogs caused by canine influenza v

231 in mammals.IMPORTANCE Canine influenza is a respiratory disease of dogs caused by two CIV subtypes,

232 ne viral arteritis (EVA), a reproductive and respiratory disease of horses.

233 rus (IBV) causes an acute, highly contagious respiratory disease of poultry.

234 he primary bacterial species associated with respiratory disease of ruminants.

235 Ovine pulmonary adenocarcinoma is a chronic respiratory disease of sheep caused by jaagsiekte sheep

236 ors (OR, 5.05; 95% CI, 1.90-13.39), previous respiratory diseases (OR, 4.54; 95% CI, 1.36-15.10), and

237 elf-rated health, cancer, heart disease, and respiratory disease (ORs of two to three), strong for se

238 A are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular diseas

239 mpanzee communities in the course of several respiratory disease outbreaks.

240 he Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort.

241 c data (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes [U-BIOPRED] cohorts) by mea

242 and the Unbiased BIOmarkers in PREDiction of respiratory disease outcomes [U-BIOPRED] project) and us

243 of the Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes adult patient cohort at bas

244 = 429), Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes adults (n = 96), Unbiased B

245 = 96), Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes pediatric participants (n =

246 IOPRED (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes) study.

247 cohort (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes, U-BIOPRED).

248 he Unbiased BIOmarkers for the PREDiction of respiratory diseases outcomes cohort, of whom 595 had se

249 costeroids (P: 0.007) and history of chronic respiratory disease (P: 0.05) increased the likelihood o

250 to pre-existing trends, while mortality from respiratory diseases (p = 0.053) and transport accidents

251 causative agent of the ongoing severe acute respiratory disease pandemic COVID-19.

252 rrelated with individual characteristics and respiratory disease parameters.

253 n to the use of the technology in diagnosing respiratory diseases, potential niche applications, and

254 Preoperative respiratory disease predicted pneumonia (P=0.043).

255 A high proportion of cornea donors have respiratory disease prior to donation.

256 ngeal flora, contributing to the severity of respiratory disease progression.

257 nd positive effects of BMI on mortality from respiratory disease, prostate cancer, and lung cancer, w

258 stood and vary by phenotype of chronic lower respiratory disease.PurposeTo use four-dimensional (4D)

259 e epidemic wave and with the return of other respiratory diseases, radiologists can play an important

260 Asthma is a heterogeneous respiratory disease reflecting distinct pathobiologic me

261 reened for SUDEP, epilepsy, heart disease or respiratory disease-related genes from previous publishe

262 We hypothesize that this may be explained by respiratory disease-related systems instability and loss

263 esis of human rhinovirus (HRV) during severe respiratory disease remains undefined; thus, we aimed to

264 heart failure), and 2,436 incident cases of respiratory disease (respiratory death or nonfatal chron

265 ssociated with markers of cardiovascular and respiratory disease risk.

266 from 85 individuals with and without chronic respiratory disease (severe asthma, chronic obstructive

267 virus (RSV) associated with increased acute respiratory disease severity in a cohort of previously h

268 2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte

269 steroidal anti-inflammatory drug-exacerbated respiratory disease status at screening, previous surger

270 ved for deaths due to heart disease, cancer, respiratory disease, stroke, diabetes, and kidney diseas

271 ties which are of great interest in treating respiratory diseases such as acute lung injury (ALI), ac

272 lth assessment, diagnosis, and treatment for respiratory diseases such as asthma, chronic bronchitis,

273 observed in association with several chronic respiratory diseases such as asthma, cystic fibrosis, br

274 at may help in the subphenotyping of chronic respiratory diseases such as asthma.

275 rrounding teeth, can influence the course of respiratory diseases, such as asthma, due to epithelial

276 c severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are havi

277 ring facility with a cluster of workers with respiratory disease supports cross-pollination of microb

278 rd of hospitalizations due to COPD and other respiratory diseases than did those without.

279 Asthma is a chronic and genetically complex respiratory disease that affects over 300 million people

280 cterium tuberculosis (M. tb.) is a pervasive respiratory disease that could benefit from treatments t

281 Asthma is a common chronic respiratory disease that has a heritable component.

282 se 2019 (COVID-19) is a novel, viral-induced respiratory disease that in ~10-15% of patients progress

283 TANCE Influenza A virus (IAV) causes a human respiratory disease that is associated with significant

284 We focus on asthma and COPD, two chronic respiratory diseases that have been long hypothesized to

285 reated with remdesivir did not show signs of respiratory disease; they also showed reduced pulmonary

286 indirect contact transmission route in some respiratory disease transmission and providing data for

287 t lead to the development and progression of respiratory diseases, treatment options remain limited.

288 Forty-two subjects with aspirin-exacerbated respiratory disease underwent an aspirin desensitization

289 To identify distinct classes of allergic respiratory diseases using latent class analysis (LCA) a

290 iation between short-term ozone exposure and respiratory diseases was robust.

291 A total of 4616711 deaths due to chronic respiratory diseases were recorded in the United States

292 y, a neutral scenario emerged for cancer and respiratory diseases, where we found no differences in m

293 ARS-CoV-2 replication and develop pronounced respiratory disease, which may more accurately reflect h

294 against others of the same subtype or common respiratory diseases while still exhibiting fast binding

295 Asthma is a chronic respiratory disease with marked clinical and pathophysio

296 ) that results in excessive inflammation and respiratory disease, with cytokine storm and acute respi

297 ire cross pigs with RESTV resulted in severe respiratory disease, with most animals reaching humane e

298 ond leading viral causes of severe pediatric respiratory disease worldwide.

299 foot, and mouth disease (HFMD) and pediatric respiratory disease worldwide.

300 hand, foot, and mouth disease and pediatric respiratory disease worldwide.